Literature DB >> 10411655

Characterization of a truncated recombinant form of human membrane type 3 matrix metalloproteinase.

T Shimada1, H Nakamura, E Ohuchi, Y Fujii, Y Murakami, H Sato, M Seiki, Y Okada.   

Abstract

Membrane type 3 matrix metalloproteinase (MT3-MMP), an activator for the zymogen of MMP-2 (proMMP-2, or progelatinase A), is known to be expressed in human placenta, brain, lung and rat vascular smooth muscle cells, but information about its biochemical properties is limited. In the present study, we expressed and purified a truncated form of MT3-MMP lacking the transmembrane and intracytoplasmic domain (DeltaMT3) and characterized the enzyme biochemically. DeltaMT3 digested type III collagen into characteristic 3/4- and 1/4-fragments by cleaving the Gly781-Ile782 and Gly784-Ile785 bonds of alpha1(III) chains. Although DeltaMT3 did not have such an activity against type I collagen, it attacked the Gly4-Ile5 bond of the triple helical portion of alpha2(I) chains, leading to removal of the crosslink containing N-terminal telopeptides. By quantitative analyses of the activities of DeltaMT3 and a similar deletion mutant of MT1-MMP (DeltaMT1), DeltaMT3 was approximately fivefold more efficient at cleaving type III collagen. DeltaMT3 also digested cartilage proteoglycan, gelatin, fibronectin, vitronectin, laminin-1, alpha1-proteinase inhibitor and alpha2-macroglobulin into almost identical fragments to those given by DeltaMT1, although carboxymethylated transferrin digestion by DeltaMT3 generated some extra fragments. The activity of DeltaMT3 was inhibited by tissue inhibitor of metalloproteinases-2 (TIMP-2) and TIMP-3 in a 1 : 1 stoichiometry, but not by TIMP-1. ProMMP-2 was partially activated by DeltaMT3 to give the intermediate form. These results indicate that, like MT1-MMP, MT3-MMP exhibits proteolytic activities against a wide range of extracellular matrix molecules. However, differences in the proMMP-2 activation and tissue distribution suggest that MT3-MMP and MT1-MMP play different roles in the pathophysiological digestion of extracellular matrix.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10411655     DOI: 10.1046/j.1432-1327.1999.00459.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  22 in total

Review 1.  MMPs and TIMPs--an historical perspective.

Authors:  J Frederick Woessner
Journal:  Mol Biotechnol       Date:  2002-09       Impact factor: 2.695

2.  Metalloendoprotease cleavage triggers gelsolin amyloidogenesis.

Authors:  Lesley J Page; Ji Young Suk; Mary E Huff; Hee-Jong Lim; John Venable; John Yates; Jeffery W Kelly; William E Balch
Journal:  EMBO J       Date:  2005-11-10       Impact factor: 11.598

Review 3.  Matrix metalloproteinase collagenolysis in health and disease.

Authors:  Sabrina Amar; Lyndsay Smith; Gregg B Fields
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2017-04-26       Impact factor: 4.739

4.  Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human oral squamous cell carcinomas: implications for lymph node metastasis.

Authors:  T Shimada; H Nakamura; K Yamashita; R Kawata; Y Murakami; N Fujimoto; H Sato; M Seiki; Y Okada
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

5.  Cell surface chondroitin sulfate glycosaminoglycan in melanoma: role in the activation of pro-MMP-2 (pro-gelatinase A).

Authors:  Joji Iida; Krista L Wilhelmson; Janet Ng; Peter Lee; Charlotte Morrison; Eric Tam; Christopher M Overall; James B McCarthy
Journal:  Biochem J       Date:  2007-05-01       Impact factor: 3.857

Review 6.  Matrix metalloproteinases in the brain and blood-brain barrier: Versatile breakers and makers.

Authors:  Ralf G Rempe; Anika M S Hartz; Björn Bauer
Journal:  J Cereb Blood Flow Metab       Date:  2016-06-20       Impact factor: 6.200

7.  Differences between scirrhous and non-scirrhous human gastric carcinomas from the aspect of proMMP-2 activation regulated by TIMP-3.

Authors:  Takeyoshi Yokoyama; Hiroyuki Nakamura; Yoshihide Otani; Tetsuro Kubota; Noboru Fujimoto; Motoharu Seiki; Masaki Kitajima; Yasunori Okada
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

8.  New Strategies for the Next Generation of Matrix-Metalloproteinase Inhibitors: Selectively Targeting Membrane-Anchored MMPs with Therapeutic Antibodies.

Authors:  Laetitia Devy; Daniel T Dransfield
Journal:  Biochem Res Int       Date:  2010-10-28

Review 9.  Myocardial remodeling in viral heart disease: possible interactions between inflammatory mediators and MMP-TIMP system.

Authors:  Matthias Pauschinger; Kumaran Chandrasekharan; Heinz-Peter Schultheiss
Journal:  Heart Fail Rev       Date:  2004-01       Impact factor: 4.214

10.  Membrane-type MMPs enable extracellular matrix permissiveness and mesenchymal cell proliferation during embryogenesis.

Authors:  Joanne Shi; Mi-Young Son; Susan Yamada; Ludmila Szabova; Stacie Kahan; Kaliopi Chrysovergis; Lauren Wolf; Andrew Surmak; Kenn Holmbeck
Journal:  Dev Biol       Date:  2007-10-23       Impact factor: 3.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.